Flavone derivatives and uses in targeting ck2-mediated diseases and conditions

A compound according to formula I, or a pharmaceutically acceptable salt, hydrate, stereoisomer, or tautomer thereof:

• where R1 is halo, H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —SF5, or -L-Q where L is a linker and Q is an E3-ligase binding moiety;
• R2 is H, —O(CH2)mRa where m is an integer greater than or equal to zero, or -L-Q;
• R3 is halo, H, ORa,
• a hydrophobic group, or -L-Q;
• R4 and R5 independently are H or —ORa;
• Ra is substituted or unsubstituted aliphatic, H, substituted or unsubstituted heteroaliphatic, or acyl;
• and
• R6 is
• where
• R7A is N or CH and R7B is N or CH where one or both of R7A and R7B is N, R7C is C—R8, R7D is C—R10, and R7E is C—R9,
• R8 is —ORa, H, substituted or unsubstituted alkyl, or halo, R9 is —ORa, —CN, —C(O)ORa, or azole, and R10 is H, alkynyl, -alkynyl-R11, -alkynyl-heteroaliphatic, halo, —ORa, or a hydrophobic group, or R8/R9 or R9/R10 together with the atoms to which they are bound form a substituted or unsubstituted heteroaliphatic or heteroaryl ring, and
• R11 is substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl.